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L
eptin and adiponectin, two fat tissue hormones, are
increased or tend to be increased in patients with
rheumatoid arthritis (RA).1 2 They are likely to be
stimulated by proinflammatory cytokines such as tumour
necrosis factor (TNF),3 4 and both were found to be increased
in the synovial fluid of patients with RA.1 2 Thus, one would
expect lowering of serum levels of these two hormones
during anti-TNF antibody treatment.
As part of a recently published study with adalimumab
(Abbott SpA, Campoverde di Aprilia, Italy),5 we included 32
white patients with RA (30 postmenopausal women, two
men) fulfilling the American College of Rheumatology
criteria for RA.6 The patients were selected according to the
inclusion criteria of the adalimumab Research in Active RA
study (ReAct). A total of 16 patients (15 female, one male)
did not receive parallel or prior (6 months before) predniso-
lone treatment. The other 16 patients (15 female, one male)
received prednisolone treatment (mean (SEM) 4.6 (0.2) mg/
day). The initial mean (SEM) body mass index in the two
groups was 22.8 (0.8) kg/m2 (without prednisolone) and 22.3
(0 8) kg/m2 (with prednisolone). We did not see any obvious
change of body weight throughout the study. All patients
were given additional methotrexate (stable throughout this
study) but no other immunosuppressive drugs. Patients were
assigned to receive single self-injections of adalimumab
subcutaneously at 40 mg every other week. A baseline blood
sample was taken 1–2 weeks before the start of adalimumab
treatment. Anti-TNF antibodies were infused on weeks 0, 2,
4, 6, 8, 10, and 12. For this study, patients were clinically
investigated and blood was drawn between 8 am and 9 am
when the patients visited the outpatient clinic on the baseline
day and at weeks 2, 6, and 12. The blood was immediately
centrifuged and serum was stored at 280 C˚. The study was
approved by the ethics committee of L Sacco University
Hospital, Italy.
We used enzyme immunometric assays for the quantitative
determination of serum levels of leptin (IBL, Hamburg,
Germany), adiponectin (R&D Systems, Wiesbaden, Germany),
and interleukin (IL)6 (R&D Systems). Intra-assay and inter-
assay coefficients of variation for all tests were ,10%.
Table 1 shows that during 12 weeks of adalimumab
treatment in patients, with and without prednisolone, typical
measures of inflammation markedly decreased. This indi-
cates that adalimumab was effective in reducing RA
associated inflammation. However, serum levels of leptin
and adiponectin did not change during adalimumab treat-
ment (fig 1). Interestingly, although having similar body
mass indices, patients with prior prednisolone treatment had
markedly decreased serum levels of adiponectin in compar-
ison with patients without glucocorticoids (fig 1). This
difference remained constant throughout the observation
period (fig 1).
In this study, we expected a decrease of serum levels of
leptin and adiponectin in patients with RA receiving
adalimumab treatment because both hormones are thought
to be stimulated by proinflammatory cytokines such as
TNF.3 4 We do not believe that an increase of body fat mass
has masked a leptin fall because not one anti-TNF treatment
study has reported a dramatic effect on body fat mass (even
in inflammatory bowel diseases). In addition, others did not
find a correlation between serum levels of leptin and disease
activity in patients with RA and juvenile arthritis,7 8 which
may demonstrate that in these patients the link between
inflammation and serum levels of leptin is probably not
strong. This finding was later confirmed by another group.9
Others have demonstrated that serum leptin levels are
inversely correlated with markers of inflammation such as
C reactive protein.10 In our study we did not find any
correlation between serum levels of leptin or adiponectin and
the number of swollen joints or tender joints, serum IL6, C
reactive protein (data not shown, but p values are .0.2).
However, adiponectin levels were lower in the patients with
RA who had been treated with prednisone; the reason for this
is presently unknown.
In conclusion, in patients with RA, serum levels of leptin
and adiponectin are not linked to inflammation and are not
down regulated by 12 weeks of anti-TNF treatment.
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Table 1 Course of response measures during 12 weeks of adalimumab treatment
Time
Swollen joints*
(n)
Tender joints*
(n)
Patient’s global
assessment of pain* (VAS)
IL6 serum levels*
(pg/ml)
Baseline 8.8 (0.7) {9.1 (0.6)} 10.5 (0.8) {9.5 (0.5)} 54.8 (4.5) {54.8 (3.7)} 21.6 (7.4) {33.9 (12.2)}
Week 2 7.3 (0.9) {7.0 (0.7)} 9.6 (0.7) {8.1 (0.5)} 40.8 (3.5) {40.7 (5.3)} 4.1 (1.8) {7.0 (1.8)}
Week 6 4.3 (0.9) {4.3 (0.6)} 7.5 (0.80) {6.5 (0.7)} 32.3 (3.8) {38.5 (3.8)} 8.7 (5.3) {5.5 (2.1)}
Week 12 2.8 (0.5) {3.4 (0.6)} 6.1 (0.5) {5.4 (0.7)} 23.3 (3.7) {25.2 (4.7)} 2.9 (0.9) {13.8 (8.5)}
Data of patients with prednisolone treatment are given in {brackets}. Data are given as means (SEM).
*p,0.003 indicating a decrease as assessed by the Friedman test.
970 Letters
www.annrheumdis.com
Conflict of interest: None.
Correspondence to: Professor R H Straub, rainer.straub@
klinik.uni-regensburg.de
Accepted 4 November 2005
REFERENCES
1 Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the
inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis
2003;62:952–6.
2 Scha¨ffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scho¨lmerich J, et al.
Adipocytokines in synovial fluid. JAMA 2003;290:1709–10.
3 Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegler R, Nawroth PP.
Tumor necrosis factor increases serum leptin levels in humans. J Clin
Endocrinol Metab 1997;82:4080–2.
4 Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM. Induction of
adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro
studies. Endocrinology 2004;145:5589–97.
5 Straub RH, Sarzi-Puttini P, Atzeni F, Buttgereit F, Carrabba M, Cutolo M.
Anti-tumour necrosis factor antibody treatment does not change serum
levels of cortisol binding globulin in patients with rheumatoid arthritis but it
increases androstenedione relative to cortisol. Ann Rheum Dis
2005;64:1353–6.
6 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
7 Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M. Leptin serum
levels are not correlated with disease activity in patients with rheumatoid
arthritis. Metabolism 1999;48:745–8.
8 Perfetto F, Tarquini R, Simonini G, Bindi G, Mancuso F, Guiducci S, et al.
Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional
status? Ann Rheum Dis 2005;64:149–52.
9 Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D.
Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin
levels with bone mass and body composition in patients with rheumatoid
arthritis. Rheumatology (Oxford) 2005;44:120–5.
10 Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.
Markers of inflammation are negatively correlated with serum leptin in
rheumatoid arthritis. Ann Rheum Dis 2005;64:1195–8.
12
10
6
8
4
2
0
12
Time (weeks)
A
Se
ru
m
 le
pt
in
 (n
g/
m
l)
0 84
20 000
16 000
8000
12 000
4000
0
12
Time (weeks)
pGLM < 0.001
B
Se
ru
m
 a
di
po
ne
ct
in
 (n
g/
m
l)
0 84
Figure 1 Course of serum levels of leptin (A) and adiponectin (B) in patients with RA with (black symbols) and without (white symbols) prednisolone
treatment. A comparison of the two groups in (B) was carried out using the general linear model (GLM) statistical technique. The Friedman test indicated
no significant change during the course of adalimumab treatment. The dashed lines indicate lower and upper limits of the normal range in women.
Data are given as means (SEM).
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M
yelopathy is a rare manifestation of systemic lupus
erythematosus (SLE). The standard treatment con-
sists of high dose corticosteroids and intravenous
pulse cyclophosphamide (CYC).1 2 Despite this, our previous
experience indicated that half of the patients with lupus
related myelopathy did not respond completely to CYC
treatment.3 Moreover, toxicities of CYC are of major concern,
particularly severe infections and ovarian failure.4 Therefore,
less toxic or more effective alternative treatments are needed.
Mycophenolate mofetil (MMF) is a relatively new
immunosuppressive agent that has increasingly been used
in patients with SLE because of its favourable efficacy and
safety.5 Controlled trials have confirmed its efficacy in the
induction and maintenance treatment of proliferative lupus
nephritis.6 7 MMF has also been reported to be useful in
refractory multiple sclerosis.8 However, information about
the efficacy of MMF in neuropsychiatric SLE is scant. We
here report our preliminary experience of the use of
combined corticosteroid and MMF in the treatment of lupus
related myelopathy.
Three patients who fulfilled the 1982 American College of
Rheumatology criteria for SLE and had acute myelopathy
were treated with a protocol consisting of high dose
corticosteroids (daily intravenous methylprednisolone pulses
(15 mg/kg) for 3 days, followed by oral prednisolone 0.6 mg/
kg/day for 6 weeks, then tapered by 5 mg/week until
,10 mg/day) and MMF (2 g/day for 6 months, followed by
1 g/day in two divided doses). Intravenous immunoglobulin
for one course (5 days of 0.4 g/kg) could be given as rescue
treatment if the response was suboptimal. Rehabilitative
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